antimalarial
Experimental TherapeuticsPopulation Pharmacokinetics of Tafenoquine, a Novel AntimalarialTafenoquine is a novel 8-aminoquinoline antimalarial drug recently approved by the U.S. Food and Drug Administration (FDA) for the radical cure of acute Plasmodium vivax malaria, which is the first new treatment in almost 60 years.
- Experimental TherapeuticsPrediction Model for Antimalarial Activities of Hemozoin Inhibitors by Using Physicochemical Properties
- Mechanisms of Action: Physiological EffectsThe Candidate Antimalarial Drug MMV665909 Causes Oxygen-Dependent mRNA Mistranslation and Synergizes with Quinoline-Derived Antimalarials
- Experimental TherapeuticsSimplified Reversed Chloroquines To Overcome Malaria Resistance to Quinoline-Based Drugs